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Abstract
Patients suffering from malignant diseases receive very often highly emetogenic chemotherapy as part of their treatment. 
With the aim of assessing the efficacy of cannabinoids in treating chemotherapy-induced nausea and vomiting (CINV), we searched 
the literature published until April 2020 in Medline/PubMed, Embase, the Cochrane Controlled Trials Register, and in specific web 
pages. Randomized clinical trials comparing cannabinoids efficacy in managing CINV with that of placebo reported absence of vomit-
ing (3 trials, 168 patients) and absence of nausea and vomiting (3 trials, 288 participants). In comparison with patients receiving other 
antiemetics, patients receiving cannabinoids reported no nausea (5 trials, 258 participants), no vomiting (4 trials, 209 participants), 
and absence of both (4 trials, 414 patients). Across all trials, cannabinoids were more effective in relieving the symptoms of nausea and 
vomiting induced by cytotoxic therapy than placebo was and slightly better than conventional antiemetics. A retrospective review com-
paring nabilone, dronabinol, delta-9-THC, and delta 8-THC with other antiemetics used to manage CINV in pediatric patients showed 
that these drugs could also be used as adjuvant antiemetics. Cancer patients on highly emetogenic chemotherapy but with insufficiently 
effective standard antiemetic therapy can be given cannabis preparations containing similar amounts of tetrahydrocannabinol and can-
nabidiol, which should be received in strict compliance with the professional guidelines for the treatment of CINV. 
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INTRODUCTION
Patients suffering from malignant diseases are most often 
treated with highly emetogenic chemotherapy as part of 
their treatment. Although cannabinoids have been shown 
to cause excessive nausea and vomiting, their antiemetic 
effect in cancer patients experiencing chemotherapy-indu-
ced nausea and vomiting is also well-known. 
Cannabinoids for CINV
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Therapeutic potential of cannabis
In traditional medicine, cannabis preparations have been 
used for thousands of years in the treatment of various 
conditions such as chronic pain, spasticity, cancer, seizu-
re disorders, nausea, anorexia, and infectious diseases.1 As 
medicinal use of cannabis preparations is widely restricted 
in many countries for legal and ethical reasons, there is a 
lack of evidence-based medical information that can cor-
roborate potential benefit of the therapy. Cannabis is used 
for medical purposes mostly by patients suffering from 
cancer-related pain. Although medicinal use of cannabis is 
regarded primarily as use of a symptom-relieving agent in 
most disorders, cancer patients using the substance tend to 
perceive it a therapeutic agent capable of curing cancer. The 
question whether cannabis can be used in the treatment of 
malignant diseases is rather controversial: there is no pu-
blished data to show that cannabinoids alone or in combi-
nation with conventional therapy can cure any malignant 
disease in humans. In contrast, there are extremely large 
numbers of publications that confirm the antitumour ef-
fects of cannabis in cell cultures and animal models.2-5 Ho-
wever, cell cultures and animal models are not sufficient to 
make rational assumption of therapeutic efficacy of canna-
bis in humans. There are several positive experiences of the 
use of cannabinoids in patients with malignant diseases, 
especially in alleviating the sickness, nausea, and vomiting 
associated with the use of cytotoxic therapy, pain relief and 
stimulation of appetite (treatment of cachexia). The bene-
fit of cannabinoid therapy for these indications have been 
shown in many randomized controlled clinical trials.6 
A cannabis extract was approved for clinical use for the 
first time in Germany in 2011 for the treatment of mode-
rate to severe refractory spasticity in multiple sclerosis.6 
Later, the National Association of Statutory Health Insu-
rance Physicians, and the Drug Commission of the Ger-
man Medical Association issued the following statement: 
“The benefit of treatment with cannabinoids for a number 
of medical indications has been shown in controlled tri-
als in which predominantly standardized and/or synthetic 
cannabinoid preparations were used. The use of such pre-
parations may therefore be reasonable for patients in whom 
conventional treatment does not achieve adequate relief of 
symptoms such as spasticity, pain, nausea, vomiting, or loss 
of appetite”.6 
Mechanism of action of cannabinoids 
and the role of endocannabinoid system 
to relief the symptoms of nausea and 
vomiting
Cannabinoids possess numerous physiological actions be-
cause of binding to cannabinoid receptors in the human 
body: the CB1 receptors (predominantly centrally located) 
and the CB2 receptors (predominantly with a peripheral 
position). Both receptors are coupled to G-inhibitory pro-
teins and are linked to signalling cascades in which ade-
nylyl cyclase and cyclic adenosine monophosphate (cAMP) 
are involved.7 
The finding that the blockade of one subtype of the sero-
tonin (5-HT) receptor, the 5-HT3 receptor, may suppress 
emesis, was a major advance in the control of acute emesis 
in chemotherapy.8 Cannabinoid receptor agonists directly 
inhibit the function of the peripheral 5-HT3 receptors.
9 The 
first evidence of an interaction between endocannabinoids 
and 5-HT3 receptors was detected by the finding that anan-
damide inhibits 5-HT3 receptor in rat nodose ganglion 
cells.10 But it is also known that 5-HT3 antagonists are less 
effective in reducing acute nausea than suppressing acute 
vomiting. Also, 5-HT3 antagonists are ineffective in redu-
cing delayed (24 hours later) nausea and vomiting.11-13 
There is plenty of evidence suggesting that the endocan-
nabinoid system can be an effective target in the protection 
from chemotherapy-induced vomiting, whereas the effect 
on nausea seems to be limited.14 It is assumed that the en-
docannabinoid system inhibits emesis physiologically, by 
activating the CB1 and CB2 receptors localized in the dorsal 
vagal complex of the brainstem where emetic reflexes are 
located.15 After the discovery of CB1 and CB2 receptors and 
the discovery of specific cannabinoid receptor agonists and 
antagonists, the cannabinoids and the endocannabinoid 
system are under intensive scientific interest. 
Chemotherapy-induced nausea and 
vomiting (CINV)
Nausea and vomiting (emesis) are important elements in 
defensive or protective human responses. These responses 
are sometimes manifested as symptoms of disease, but so-
metimes there are side effects of various medications, es-
pecially chemotherapy used to treat cancer.16-18 CINV are 
categorized as acute, delayed, anticipatory, breakthrough or 
refractory.19
Мany neurotransmitters primarily binding to seroto-
nin, neurokinin-1, and dopamine receptors are involved 
in this process.20,21 The frequency of nausea and vomiting 
depends primarily on the emetogenic potential of the che-
motherapeutic agents that are used.22 Approximately about 
45% to 60% of patients with malignant disease experience 
CINV.23-26 About 70% of patients receiving highly emeto-
genic chemotherapy are protected from acute emesis by 
administration of antiemetic therapy. But 30% of patients 
have symptoms in the delayed phase.22 The primary goal of 
antiemetic therapy is to prevent CINV27 with appropriate 
medications.28 There are several antiemetic options for al-
leviating symptoms of nausea and vomiting and managing 
CINV: corticosteroids, serotonin receptor antagonists (5-
HT3 antagonists) and neurokinin receptor antagonists (NK1 
antagonists). Also, many alternative medicines such as an-
tihistamines, benzodiazepines, anticonvulsants, and some 
antagonists of dopamine receptor are used to prevent and 
manage CINV. Although with newer antiemetics such as 
ondansetron and aprepitant, vomiting can be well managed, 
nausea is still not properly controlled.29 The negative side of 
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medicines that belong to these classes is that they have lower 
efficacy and are associated with more adverse effects.30,31 
The antiemetic effect of cannabinoids in patients with 
malignant disease treated with highly emetogenic antitu-
mour therapy is well known and proven.32-40 The initial in-
centive for emesis is the release of serotonin (5-HT) from 
enterochromaffin cells that are distributed across the entire 
epithelium of the gastrointestinal tract.41 Observations that 
the CB1 agonist WIN 55,212-2 reduced serotonin release 
evoked by the emetogenic Staphylococcal enterotoxin42, 
suggest that inhibiting the serotonin release from enter-
ochromaffin cells might be selectively targeted to reduce 
emesis triggered by cancer chemotherapeutics.
Cannabinoids achieve their antiemetic effect by acting as 
agonist predominantly on CB1 receptors.
43 It is important 
to emphasize that the use of cannabis is not recommended 
for management of CINV and is not part of the NCCN Cli-
nical Practice Guidelines in Oncology (NCCN Guidelines) 
for antiemesis43 because there is not enough medically ba-
sed evidence and because of legal concerns. And yet, there 
are many testimonials and positive experiences from the 
use of cannabis preparations for the treatment of various 
painful conditions.
Approved cannabis-based medications 
for CINV
Two medicines: nabilone (Cesamet) and dronabinol (Mari-
nol) are approved for “prevention/treatment of chemothe-
rapy-induced nausea and vomiting” in many countries.
Cesamet (nabilone) is a synthetic cannabinoid for oral 
administration with therapeutic use as an antiemetic and as 
an adjunct analgesic for neuropathic pain. It mimics tetra-
hydrocannabinol (THC). The antiemetic effect of nabilone 
is caused by interaction with the cannabinoid CB1 receptor 
system. It is approved by the FDA for oral administration. 
It is an analogue of dronabinol, and is available freely in 
Canada (categorized in level II of controlled substances). 
Approved indications are: treatment of severe vomiting re-
lated to chemotherapy in malignant cases in patients who 
do not respond adequately to conventional antiemetic the-
rapy (age 18-65 years).44 The restriction is required becau-
se of the data that disturbing psychotomimetic reactions 
which are not observed with other antiemetic agents can 
be expected in a significant number of patients treated with 
Cesamet (nabilone).
Marinol (dronabinol) is a synthetic THC for oral ad-
ministration approved also by the FDA. As a prescription 
medicine, it is approved in the USA, the Netherland and 
Germany for two indications: treatment of anorexia asso-
ciated with weight loss in people with acquired immune 
deficiency syndrome (AIDS) and vomiting caused by che-
motherapy in people whose nausea and vomiting have not 
improved with usual anti-nausea medicines. In the United 
States, Marinol is considered a non-narcotic drug with a 
very low risk of physical and mental dependence (categori-
zed as level III of controlled substances).45 The mechanism 
of action of Marinol is not completely understood. Animal 
studies with other cannabinoids suggest that Marinol’s an-
tiemetic effects may be due to the inhibition of vomiting 
control mechanism in the medulla oblongata.
Nabilone and dronabinol have shown superiority as do-
pamine receptor antagonists in the prevention of CINV. 
There is some evidence that the combination of dopamine 
antagonist and cannabinoids is particularly effective in pre-
venting nausea.46
Nabilone is superior to placebo, domperidone and 
prochlorperazine but not to metoclopramide or chlorpro-
mazine.47 Although dronabinol is approved for the treat-
ment of chemotherapy induced vomiting, some clinical 
studies show that it can induce emesis.48 
MATERIALS AND METHODS
For the purpose of this paper, an electronic search was 
made using Medline/PubMed, Embase, the Cochrane Con-
trolled Trials Register (TRIALS CENTRAL) and a systema-
tic review of randomized clinical trials (RCTs) in order to 
evaluate the effectiveness and tolerability of cannabis-based 
medications for chemotherapy-induced nausea and vomi-
ting in patients with cancer. 
A systematic review of RCTs using key words: canna-
binoids, nausea, vomiting, CINV, tetrahydrocannabinol 
and RCTs, conducted till April 2020 screened 198 reports 
from which only 79 were relevant RCTs, based on title and 
abstract screening. Seven of them had no relevant infor-
mation obtained as full-text studies, 28 were in other cli-
nical examinations (pain49-52, HIV/AIDS53, ulcerative 
colitis54,55, Crohn’s disease56, epilepsy57-60, multiple sclero-
sis61-63, autism spectrum disorder64, Alzheimer’s disease65, 
psychosis66-68), in five emesis was reported, five reports 
were duplicates (they contained data that had previously 
been published) (Fig. 1).
We have examined whether there is evidence that can-
nabinoids has antiemetic effects when given at the same 
time with emetogenic chemotherapy, how well cannabi-
noids work for this indication compared to placebo or con-
ventional antiemetics, whether the effect is dose dependent 
and the profile of adverse effects.
CRITICAL REVIEW
Systematic review of RCTs conducted 
to August 2000 69-71
Thirty RCTs that compare efficacy of cannabis preparations 
(oral nabilone in 16 trials, oral drobaninol in 13 trials and 
intramuscular levonantradol in one trial) for this indicati-
ons (nausea and vomiting) to placebo and to other antie-
metics (prochlorperazine in 12 trials, metoclopramide in 
4 trials, chlorpromazine in 2 trials, thiethylperazine in one 
Cannabinoids for CINV
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198 Titles and abstracts screened 
119 Excluded reports 
79 Full reports assessed 
45 Excluded reports 
16 Pain  
7 No relevant information 
5 Reported emesis 
5 Duplicates (contained data previously published) 
12 Other clinical disorders (HIV/AIDS etc.) 
34 RCTs included - evaluating the efficacy of 
cannabinoids to relieve symptoms of CINV. 
Figure 1. Flowchart of studies through the review process. 
trial, haloperidol in one trail, domperidone in 2 trials and 
alizapride in one trial) which involves 1366 chemotherapy 
patients analysed. None of these trials compares efficacy of 
cannabinoids with newer antiemetic drugs such as ondan-
setron. Nabilone doses ranged from 1 mg per 24 hours (in 
children) up to 8 mg per 24 hours (in adults). Dronabinol 
was given according to body surface area in square meters, 
in doses ranging from 10 mg/m2 twice a day to 15 mg/m2 
six times per day. The observation period was clearly defin-
ed as 24 hours (acute antiemetic efficacy). 
In comparison with placebo, people report complete 
absence of vomiting (3 trials, 168 patients) and complete 
absence of nausea and vomiting (3 trials, 288 participants). 
The percentage of variability in effect shows low to mode-
rate quality evidence due to heterogeneity. In comparison 
with other antiemetics, there was no evidence of a diffe-
rence between cannabinoids and prochlorperazine. Par-
ticipants report no nausea (5 trials, 258 participants), no 
vomiting (4 trials, 209 participants) and complete absence 
of both (4 trials, 414 patients). The quality of evidence was 
low to moderate.
Side effects in this studies are common for cannabinoids, 
and although some may be potentially beneficial (eupho-
ria, high sedation) which were reported as a preference for 
cannabinoids compared with prochlorperazine (7 trials, 
695 participants), others were potentially serious (dyspho-
ria, depression, hallucinations, confusion headaches, visi-
on problems, dizziness, abdominal pain, dizziness, nausea, 
paranoid reaction) and are likely to limit their widespread 
use. There was weaker evidence for efficacy of cannabi-
noids in comparison with other antiemetics (metoclopra-
mide, domperidone and chlorpromazine).
Across all trials, cannabinoids were more effective in re-
lieving the symptoms of nausea and vomiting induced by 
cytotoxic therapy than placebo was and were slightly better 
than conventional antiemetics.
The conclusion that can be made from these studies is 
that cannabinoids tested in these trials indicate that canna-
bis-based medications may be useful for the treatment of 
nausea and vomiting caused by refractory chemotherapy as 
adjuvants for improving chemotherapy-related nausea and 
vomiting. Potential serious adverse effects, even when ta-
ken short-term orally or intramuscularly, are likely to limit 
their wide use. This was also later confirmed by a meta-ana-
lysis done in 2008 which covers the systematic review of the 
publications up to July 2005 in which nabilone or dronabi-
nol was evaluated with smoking marijuana.73 
Meta-analysis performed through 
Medline and PubMed up to July 2005 
in which nabilone or dronabinol was 
evaluated with “smoking marijuana”
Two systematic reviews of literature3,72 identified only two 
small RCTs in the late 1970s and early 1980s in which na-
bilone or dronabinol was evaluated with “smoking mariju-
ana”. The results of these two studies are contradictory. In 
one, smoking marijuana was worse than nabilone and not 
better than placebo, but in the second, smoking marijuana, 
as a substitute for dronabinol if the patients did not tolerate 
it (4×1 cigarettes per day, about 17.4 mg THC per cigarette 
and approximately 70 mg THC/day), showed an antieme-
tic effect (20 patients with osteosarcoma on a high dose of 
methotrexate).3,72 
In another study, the antiemetic effect of smoked marij-
uana cigarettes (8.4 mg and 16.9 mg THC per cigarette) was 
compared to a highly potent antiemetic drug (ondansetron 
8 mg). In this study 13 healthy volunteers were included, 
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and nausea and vomiting were induced by receiving syrup 
of ipecachuana. This study found that smoking marijuana 
significantly reduces nausea and slightly reduces vomiting 
compared to placebo.73 
A pilot, randomized, double blind, 
placebo-controlled phase II clinical trial
Subsequently, a small RCT in 2010, with only 16 patients, 
indicated that similar effects to relieve symptoms of nausea 
and vomiting could be expected from nabiximols (Sativex), 
but Sativex was never further developed and explored in 
that indication.37 In this placebo controlled (RCT) study, 
for nabiximols for these indications. Sixteen patients with 
tumours, receiving highly emetogenic chemotherapy were 
included, of whom seven were on nabiximols and nine on 
placebo. At the same time, they were also receiving a stan-
dard antiemetic therapy (5-HT3 antagonists). Nabiximols 
in this study was titrated as an add-on therapy to standard 
therapy in a total dose of 8.1 mg THC/7.5 mg cannabidiol 
(CBD), in three equal actions: 2.7 mg THC and 2.5 mg 
CBD two hours before chemotherapy, the second dose was 
given 30 minutes after the first dose (if the patient tolerated 
well the first dose) and the third dose 120 minutes after the 
first dose (if the patient tolerated well the second dose). All 
seven patients received all three doses. Symptoms of nausea 
and vomiting disappeared after three hours. Side effects of 
the therapy were reported only in one patient who became 
anxious, somnolent and confused with visible hallucinati-
ons. That patient was excluded from the trial and did not 
continue to use nabiximol during 4 post-chemotherapy 
days. The THC doses in this RCT were actually very similar 
to the recommended doses of dronabinol [6.2 mg THC and 
15 mg CBD per day (6 actuations every 4 hours) with the 
possibility of increasing a single dose up to maximum 130 
mg THC and 120 mg CBD per day (8 actuations every 4 
hours)]. In total, patients were using nabiximols approxi-
mately 3 days (from 1 to 5 days), and the highest average 
(per day) number of daily actuations was 5 (13.5 mg THC 
and 12.5 mg CBD). The results were: 5 out of 7 patients did 
not have delayed vomiting (vs. 2/9 on placebo), 4 out of 7 
patients did not have delayed nausea (vs. 2/9 on placebo), 
and 5 out of 7 patients had no more pronounced nausea (vs. 
4/9 at the placebo).37 
Dronabinol versus ondansetron in 
preventing delayed CINV 
A completed, still not published, double blind, randomi-
zed, placebo controlled, parallel group efficacy study of oral 
dronabinol alone and in combination with ondansetron 
versus ondansetron alone has investigated the use of drona-
binol versus ondansetron as standard antiemetic therapy in 
the prevention of delayed CINV.74 Patients were randomi-
zed into four groups. Group 1 received dronabinol (10 to 
20 mg per dose), group 2 received ondansetron (8 to 16 mg 
per dose), group 3 received combination therapy (10 to 20 
mg dronabinol + 8 to 16 mg ondansetron per dose), and 
group 4 received placebo. The primary response of nausea 
and vomiting was measured. Total response of nausea and 
vomiting/retching was defined as no vomiting and/or ret-
ching, an intensity of nausea of < 5 mm on the visual analog 
scale (VAS) and no use of rescue medication. Secondary 
Outcome Measures in time frame of 5 days were complete 
responder rate (no vomiting/retching, intensity of nausea 
of ≤ 30 mm on VAS, and no use of rescue medication), pre-
sence or absence of nausea, episodes of vomiting and/or 
retching and duration of nausea and vomiting and/or ret-
ching. Data do support the beneficial effects of dronabinol 
in managing the symptoms of delayed CINV.
A small 5-day double blind, placebo controlled RCT (a 
total of 61 patients randomized into three groups) indicates 
a similar effect of dronabinol compared to ondansetron 
and the lack of additive effects.75 Patients on highly eme-
togenic chemotherapy, pre-chemotherapy received orally 
dexamethasone (20 mg), intravenous ondansetron (16 mg) 
and placebo or dronabinol (2.5 mg). After chemotherapy, 
the patients randomized to active treatment (dronabinol 
and/or ondansetron) received dronabinol (2.5 mg) again. 
At day 2, standard doses of dronabinol (10 mg), ondan-
setron (16 mg), combination therapy of both or placebo, 
were administered. From day 3 to day 5 after chemothera-
py, the patients were on flexible doses of dronabinol (10-20 
mg), ondansetron (8-16 mg), combination of both (10-20 
mg dronabinol, 8-16 mg ondansetron) or placebo. The 
researchers concluded that dronabinol was as effective as 
ondansetron for the treatment of CINV and the combined 
therapy with both drugs was not more effective than the 
therapy with either medicine alone.
Amelioration of CINV by nabilone, 
dronabinol, delta-9-THC, and  
delta-8-THC in children
CINV remains an important side effect associated with ad-
ministration of chemotherapy in pediatrics, too. 
In one prospective randomised double blind crossover 
trial nabilone was compared with oral domperidone for 
CINV in children. Twenty-three children (aged 10 months 
to 17 years) with a variety of malignant diseases receiving 
repeated identical courses of emetogenic chemotherapy 
were given nabilone therapy. Eighteen out of 23 consecu-
tive eligible children completed the trial. The results sho-
wed that nabilone seemed to be superior to domperidone 
as an effective antiemetic for children on chemotherapy, 
even for young children. The most common side effects of 
nabilone were somnolence and dizziness, with one patient 
having hallucinations.76 
In another randomized, double-blind, crossover trial, for 
control of cancer chemotherapy-induced emesis in child-
ren, nabilone was compared with prochlorperazine. Thirty 
children (3.5 to 17.8 years of age) received two consecu-
tive identical chemotherapy cycles. Antiemetics (one cycle 
with prochlorperazine and another cycle with nabilone) 
Cannabinoids for CINV
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were given based on body weight and administered 8 to 12 
hours before chemotherapy. The total rate of improvement 
of nausea and vomiting was 70% during the treatment with 
nabilone and 30% during the treatment with prochlorpera-
zine. Sixty-six percent of children stated that they preferred 
nabilone, while 17% preferred prochlorperazine. The major 
side effects (dizziness, drowsiness, and mood swings) were 
dose related, and occurred when the nabilone dosage was 
greater than 60 micrograms/kg/d, but individual tolerance 
to nabilone varied considerably. Lower dosages of nabilone 
were associated with equivalent efficacy and without major 
side effects.77 
From 2000 to 2010 at Riley Hospital for Children at Indi-
ana University Health, the children with malignancy aged 
18 or younger receiving highly emetogenic chemotherapy 
were given at least 1 dose of dronabinol for CINV 1 to 3 
hours before chemotherapy and lower dose of other antie-
metics. Sixty percent of the patients had a defined positive 
response to dronabinol. The study concluded that drona-
binol seemed to be a viable option as an adjuvant antie-
metic in pediatric CINV, but a prospective study that uses 
patients as its own control is necessary to really define the 
place of dronabinol in therapy.78 
In two double blind studies, the anti-nausea and anti-vo-
miting effects of delta-9-tetrahydrocannabinol in children 
with cancer on chemotherapy were compared with the 
effects of metoclopramide syrup and prochlorperazine ta-
blets. THC was found to be significantly better antiemetic 
agent, but not all patients obtained relief of nausea and vo-
miting with THC. In some patients, THC increased appeti-
te during chemotherapy.79 
Delta-8-tetrahydrocannabinol (delta-8-THC) is a can-
nabinoid with lower psychotropic potency than delta-9-te-
trahydrocannabinol. In a clinical trial, delta-8-THC was gi-
ven to 8 children aged 3-13 years (18 mg/m2) with various 
hematologic cancers, treated with different antineoplastic 
drugs for up to 8 months (the total number of treatments 
with delta-8-THC was 480). The study showed that vo-
miting was completely prevented if treatment began two 
hours before each chemotherapy cycle and continued every 
6 hours for 24 hours.80 
Additionally, adverse events associated with nabilone 
in a multicenter, retrospective review of pediatric patients 
(n=110) who received nabilone plus a 5-HT3 antagonist for 
acute CINV prophylaxis were common but of minor clini-
cal significance [sedation (20.0%), dizziness (10.0%), and 
euphoria (3.6%)]. However, acute CINV control in child-
ren receiving nabilone as a part of their antiemetic regimen 
was poor in about 50% of patients who experienced com-
plete acute CINV control.81 
DISCUSSIONS
Changes in the laws of many countries to allow legalisation 
and use of cannabis for medicinal purposes are a signal that 
cannabis is increasingly recognizable globally and accepted 
as something that can really help them to manage a variety of 
medical conditions. Thus, it is especially important for peop-
le to be informed about the possible therapeutic benefits, do-
sing and adverse effects associated with the use of cannabis.
Thirteen countries of the European Union have al-
ready legalized the use of cannabis for medicinal purpo-
ses: the Czech Republic, Finland, Romania, Italy, Spain, the 
Netherlands, France, Austria, Portugal, Germany, Great 
Britain, Slovenia, and Croatia. Recently, the former Yugo-
slav Republic of Macedonia also allowed the use of canna-
bis for medicinal purposes only for four indications: treat-
ment of epilepsy, treatment of spasticity in patient suffering 
from multiple sclerosis, treatment of anorexia associated 
with weight loss in people with acquired immune defici-
ency syndrome (AIDS), and as analgesic for relieve of pain 
in patient with cancer. For this purpose, 4 different phar-
maceutical dosage forms with different ratios of THC and 
CBD are available as prescription medicines. 
But is there any justification for the use of cannabis? Are 
cannabinoids effective in relieving symptoms of nausea 
and vomiting induced by cytotoxic therapy? What is the re-
commended dose and how to titrate it? These are still open 
questions.
A systematic review of the literature published until 
April 2020 about the effectiveness and tolerability of can-
nabis-based medications for CINV in patients with cancer 
shows that cannabinoids have antiemetic effects when ad-
ministered concomitantly with emetogenic chemotherapy. 
A retrospective review of nabilone, dronabinole, delta-
9-THC, and delta 8-THC in comparison with other antie-
metics (domperidone, prochlorperazine and metoclopra-
mide) used in pediatric patients shows that these medicines 
can be used as adjuvant antiemetics.60,77,78,80 
But the entrance of new drugs in this indication, es-
pecially the newer generations of the 5-HT3 receptor an-
tagonists and the neurokinin (NK1) receptor antagonists 
(aprepitant), redefined the place and importance of canna-
binoids - due to the relatively high incidence of significant 
psychotropic effects and the need for careful dose titration. 
A meta-analysis including nearly 9000 patients receiving 
moderately and highly emetogenic chemotherapy sho-
wed that they experienced a significant improvement in 
CINV in the acute, delayed, and overall phases (p<0.001) 
when NK1 were added to 5-HT3 antagonists and corticos-
teroids.76 Currently, cannabinoids (nabilone, dronabinol) 
are considered as third or fourth line of choice, or as the last 
option in patients in which previous standard treatments 
do not achieve the desired effect.31,37,43,47,82-85
Unfortunately, a ratio of the effectiveness of cannabi-
noid compared to the effectiveness of conventional therapy 
is still unknown. Chronic use of cannabinoids can cause 
an excessive hyperemesis syndrome characterized by cyclic 
vomiting without any other recognizable reasons.86 
In regulatory approved clinical studies, dronabinol is 
only tested alone and compared with placebo and/or the 
most common phenothiazines. Only in one or two smaller 
studies was dronabinol combined with ondansetron. So, in 
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cases of failure of the standard therapy for management of 
nausea and vomiting in cancer patients on chemotherapy, 
dronabinol would be the third or fourth line of therapy, ex-
clusively as monotherapy, because the possibility of add-on 
therapy is not particularly tested.74 
However, it is important to emphasize that many pa-
tients have a strong preference for cannabinoids. In some 
cases cannabinoids might be less potent than other availa-
ble antiemetics, but for some patients they are the only 
agents that work, and they are the only antiemetics that also 
increase appetite.87 
For cancer patients on highly emetogenic chemothera-
py for whom the standard anti-CINV therapy (1 or more 
5-HT3 antagonists, corticosteroids) is not sufficient, canna-
bis preparations containing similar amounts of THC and 
CBD can be proposed, but they must be taken in accordan-
ce with the applicable professional guidelines for the treat-
ment of CINV. Based on the recommendations for the use 
of dronabinol and nabilone and the described RCT with 
nabiximols, the initial, pre-therapeutic dose should be fixed 
(7.5 mg THC and 6 mg CBD divided into 3 equal doses 
within 60 minutes pre-chemotherapy). The dosage during 
post-chemotherapy days (up to 4 days after chemotherapy) 
requires titration of the dose (if necessary) and depends on 
tolerability. After initial, pre-therapeutic dose, the recom-
mended daily dose can be increased from 16.2 mg of THC 
and 15 mg of CBD to maximum 45 mg of THC/36 mg CBD 
(depending on the need and tolerability). 
The present review focuses on the findings and quality 
of systematic reviews of cannabinoids for CINV; it shows 
that there is no high-quality evidence to recommend when 
using cannabinoids for the management of CINV.86 
CONCLUSION
The potential beneficial use of cannabinoids to relieve 
symptoms of CINV is discussed in this review. In addition, 
the role of the endocannabinoid system and its significant 
potential to manage CINV is explained. Keeping in mind 
the current guidelines for CINV as well as the FDA-ap-
proved dronabinol and nabilone in managing CINV and 
the available data from systematic reviews of RCTs, it can be 
concluded that there is justification for use of cannabinoids 
to relieve symptoms of nausea and vomiting induced by 
cytotoxic therapy. Studies of nabilone, dronabinole, delta-
9-THC, and delta 8-THC in comparison with other antie-
metics used in pediatric patients show that these medicines 
can be used as adjuvant antiemetics allowing the reduction 
of the dose of other antiemetics, and hence the occurrence 
of adverse effects. Based on the recommendations for the 
use of dronabinol and the described RCT with nabiximols 
for the treatment of multiple sclerosis (MS) we should as-
sume that a preparation containing similar amounts of 
THC and CBD (for example 2.5/2.0 mg per dose), com-
pared to the preparation recommended for patients with 
MS (2.5/1.25 mg per dose) could be an add-on therapy to 
the standard antiemetic therapy (5-HT3 antagonists, dexa-
methasone), although an add-on therapy is not particularly 
tested (two completed, still unpublished studies evaluated 
dronabinol in combination with a 5-HT3). 
We must also emphasize the fact that there is still no 
sufficient data to support the routine use of cannabinoids 
as an antiemetic in all chemotherapeutic modes. Adverse 
effect profile of cannabinoid also must be seriously consi-
dered bearing in mind the increased incidence of adverse 
effects from cannabinoids compared with conventional an-
tiemetic therapy, especially the psychotropic effects. Howe-
ver, with safe and effective available antiemetics (5HT3 and 
NK1 antagonists), oral synthetic cannabinoids (e.g. nabilo-
ne, dronabinol) can be recommended as an adjuvant thera-
py to relieve symptoms of nausea and vomiting induced by 
cytotoxic therapy. In cases of failure of the standard therapy 
for the treatment of nausea and vomiting in cancer patients 
on chemotherapy, these medicines can be considered as al-
ternative options. Due to the lack of data for efficacy and 
safety, herbal cannabis (smoking marihuana) cannot be re-
commended for CINV. 
Further research and testing regarding the potential 
antiemetic effects of cannabinoids for relief of symptoms 
CINV is needed. A prospective trial using patients as their 
own controls is necessary to truly define efficacy of canna-
binoids for the treatment of acute and delayed nausea and 
vomiting. Clinical trials in which effects of cannabinoid 
will be compared with newer antiemetics such as ondan-
setron is also very important and necessary. 
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Резюме
Пациентам, страдающим злокачественными заболеваниями, часто в рамках лечения проводят эметогенную химиотерапию.
Чтобы оценить эффективность каннабиноидов в лечении тошноты и рвоты, вызванной химиотерапией (ТРВХ), мы из-
учили литературу, опубликованную до апреля 2020 года в данных Medline / PubMed, Embase, Кокрановского реестра кон-
тролируемых испытаний и некоторых веб-сайтов. Рандомизированные клинические испытания, сравнивающие эффек-
тивность каннабиноидов в контроле ТРВХ с эффективностью плацебо, показали отсутствие рвоты (3 испытания, 168 
пациентов) и отсутствие тошноты и рвоты (3 испытания, 288 участников). По сравнению с пациентами, принимающими 
другие противорвотные средства, пациенты, принимавшие каннабиноиды, сообщали об отсутствии тошноты (5 испытаний, 
258 участников), об отсутстии рвоты (4 испытания, 209 участников) и об отсутствии тошноты и рвоты (4 испытания, 414 
пациентов). При всех экспериментах каннабиноиды были более эффективны в облегчении симптомов тошноты и рвоты, 
вызванных цитотоксической химиотерапией, чем плацебо, и были немного лучше, чем обычные противорвотные средства. 
Ретроспективный обзор, сравнивающий набилон, дронабинол, дельта-9-ТГК и дельта-8-ТГК с другими противорвотными 
средствами, используемыми при лечении ТРВХ у педиатрических пациентов, показал, что эти препараты также могут 
использоваться в качестве адъювантных противорвотных средств. Больные раком, получающие высокоэметогенную 
химиотерапию, но с недостаточно эффективной стандартной противорвотной терапией, могут принимать препараты 
каннабиса, содержащие аналогичные количества тетрагидроканнабинола и каннабидиола, которые следует принимать в 
строгом соответствии с инструкциями профессионала по лечению ТРВХ.
Ключевые слова
каннабис, каннабидиол, тошнота, тетрагидроканнабинол, рвота
